이 누리집은 대한민국 공식 전자정부 누리집입니다.
Biz News Korea(Eng)
Celltrion chooses TEVA as biosimilar distributor in N. America
- Collected
- 2016.10.07
- Distributed
- 2016.10.10
- Source
- Go Direct
Celltrion Healthcare, the marketing unit of Celltrion Group, is responsible for overseas distribution of Celltrion products.
TEVA, a multinational generic drug company, will pay $160 million upfront and will split the profit from commercializing the two biosimilars developed by Celltrion.
Of the amount, $60 million can be returned to TEVA depending on market conditions or be used as an additional upfront payment for future supplies.
Truxima’s reference drug is rheumatoid arthritis and non-Hodgkin’s lymphoma treatment Mabthera (rituximab) developed by Biogen and marketed by Roche. It is a blockbuster drug with more than $5 billion in global turnover last year. Celltrion filed an application to the EMA for marketing approval of Truxima in Oct. last year.
Herzuma’s reference drug is breast cancer treatment Herceptin developed by Roche’s subsidiary Genentech and marketed by Roche. It is also a $6.3 billion blockbuster drug.
Celltrion received marketing approval of Herzuma in Korea in Jan. 2014. A clinical trial was recently completed in early-stage breast cancer patients. The company is due to file an application to the EMA for marketing approval of the drug in the fourth quarter of this year.
The North American sales of both MabThera and Herceptin reached more than $6 billion last year. The company expects some 1.4 trillion won ($1.3 billion) a year could be generated from the two biosimilars on the assumption that their market share would reach 20 percent.
By Lee Dong-in
[ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved]